Medable sponsor looking at data on laptop
Patient-First Data Collection

A better look at your data

Build COAs, connect with sensors, and access all your data streams with an intuitive web-based platform for better decision making and submission-ready results.

Seamless, compliant, and timely study startup for sponsor and CRO study teams.

  • Build eCOA both validated instruments and eDiaries to industry standard
  • Store instruments, including translations, in your library for rapid deployment that scales across future studies
  • Dashboards and reports to stay up-to-date with all study and participant activity
  • Access and integrate a global library and marketplace of instruments, digital endpoints, and other trial tools
Medable user holding ipad

Connected and convenient

Make data collection a breeze with devices, diaries, and sensors designed to fit into participants’ everyday lives.

Remove manual entry and configuration time with intuitive and automated workflows for sites and study teams.

Get the complete picture

Stay closer to your trial and make quicker, more informed decisions with expanded data sources and an aggregated view of evidence generation.

See your trial’s progress at a glance with easy-to-use dashboards and reporting.

Medable eco dashboard
Medable worldwide map

Global expertise and compliance

Rest assured, our standardized, pre-validated builds have undergone scientific review to meet eCOA best practices.

Available in 60+ countries and 120+ languages, Medable’s Data Collection from anywhere is designed to comply with all global regulations, including FDA 21 CFR Part 11, ICH E6 (R2), and GDPR.

“Our eCOAs are designed, built, and implemented with   user experience at the forefront."
Musaddiq Khan

VP Therapeutic Area Solutions - Customer Value Team

No items found.

Frequently asked questions

What is eCOA?

eCOA stands for electronic clinical outcome assessment and uses electronic devices like tablets, desktop computers, and phones to collect data from trial participants. Participants complete diaries, questionnaires, or other prompts to communicate how they are feeling or functioning during the course of a clinical trial. eCOAs are part of the decentralized clinical trial (DCT) methodology and are essential to understanding whether a drug is reducing symptoms and improving patients’ quality of life.

What is Medable’s eCOA offering?

Medable’s eCOA offering is part of our broader evidence generation offering: Patient-First Data Collection.  Medable’s tools allow teams to build eCOA instruments (both validated instruments and eDiaries) that meet industry standards. Data collected from this system can be used for primary endpoints in pivotal studies. Study teams can store instruments, including translations, in a library for rapid deployment in future studies. Dashboards keep teams informed of all startup activities along the way. Teams may also access their library of prebuilt, validated instruments to improve study startup.

Does Medable’s support BYOD?

Yes. Medable's platform is multimodal, meaning patients can access our interface through the Patient app or a web browser. A BYOD model allows patients to use their own smartphone or other device for data capture during a site visit or remotely. Participants using devices they are already familiar with may lead to better compliance and ultimately, a better clinical trial experience. However, since some participants may be hesitant to download an app on their own device, or may not own a device that meets the requirements, it’s important to anticipate a percentage of provisioned devices, even in trials adopting a BYOD strategy.

Does Medable offer any connected sensors as part of data collection for studies?

Yes, Medable has a partnership with Withings who offers a range of medical grade and compliant devices. Adding protocol complexities like connected sensors and wearables will effect the study build time.

What is the biggest benefit to our eCOA and Connected Sensor offerings?

Medable's scalable solutions provide pathways to collect and assess objective and subjective patient data in a comprehensive, compliant, and standard manner allowing sponsors to discover clinically meaningful insights in real-time. And our web-based patient application provides a more patient-centric experience via seamless in-app reminders and task notifications, decreasing the likelihood of dropouts, inconsistent and inaccurate data and missed patient visits.

The latest in eCOA

White Papers, Case Studies, Reports

Enhancing Oncology trials with digital solutions: A focus on patient-reported outcome measures and eConsent

Over the last decade the number of oncology trials has skyrocketed, almost doubling the number of all other therapeutic areas combined, according to the WIRB-Copernicus Group¹. Known for their complex design, oncology trials often present various participant, site, and sponsor hurdles.

Sponsors and CROs looking to tackle these challenges andreduce the burden on participants and sites should explore the potential of digital solutions, particularly electronic informed consent (eConsent) and electronic patient reported outcomes (ePRO). Both tools offer expanded views of the participant journey while offering feedback that enables sponsors and CROs to enhance and refine their trials for all stakeholders.


Back to basics: What are wearables and how are they powering diversity and efficiency

Mobile health technology, like medical-grade wearabledevices, can transform patient monitoring by enabling the collection of newtypes of data and better accuracy of patient responses. This tech can increaseaccessibility of trials for patients and even increase diversity and reducepatient burden by removing geographical and travel barriers.

As a result of these myriad benefits, we’ve seen theincreasing inclusion and acceptance of wearable devices throughout clinicaltrials. Here, we’ll dive into the specifics of these helpful tools and theirimpact on the future of medicine.

White Papers, Case Studies, Reports

The Definitive Guide to Digital Evidence Generation

According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than 12 billion dollars by 2030. Sparked by the COVID-19 pandemic of 2020, the rapid ascent of patient-centered technology and the digital and decentralized trials they’ve spawned has forever changed the landscape of clinical conduct. Sponsors are increasingly turning to DCT platforms in alignment with the rise of Life Science and Software-as-a-Service (SaaS) solutions. For those who haven't made the jump yet, there are many questions, including "What is a decentralized clinical trial?" Find out with this in-depth guide to decentralized clinical trials. Uncover how they work, their benefits, and how they transform clinical development.

See how Medable can make your trials more efficient.